Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sanj Patel Sells 220,170 Shares of Company Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CEO Sanj Patel sold 220,170 shares of the firm’s stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $93.27, for a total transaction of $20,535,255.90. Following the sale, the chief executive officer owned 780,037 shares in the company, valued at approximately $72,754,050.99. The trade was a 22.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Up 2.7%

NASDAQ:KNSA traded up $2.49 during trading hours on Tuesday, hitting $93.29. 1,021,631 shares of the stock traded hands, compared to its average volume of 897,528. The company has a market cap of $7.28 billion, a price-to-earnings ratio of 71.76 and a beta of 0.07. Kiniksa Pharmaceuticals International, plc has a 1 year low of $37.02 and a 1 year high of $98.48. The stock has a 50 day moving average price of $79.67 and a 200 day moving average price of $60.56.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. The firm had revenue of $285.97 million during the quarter, compared to analysts’ expectations of $260.66 million. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. Equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Citigroup increased their price target on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Weiss Ratings downgraded Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research report on Wednesday, October 28th. Wells Fargo & Company boosted their price objective on Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, October 28th. Zacks Research lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Finally, Wall Street Zen cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $100.57.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors have recently added to or reduced their stakes in the stock. Ethic Inc. purchased a new position in shares of Kiniksa Pharmaceuticals International in the third quarter worth $726,000. Pictet Asset Management Holding SA boosted its position in shares of Kiniksa Pharmaceuticals International by 41.3% during the third quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock worth $64,182,000 after acquiring an additional 251,578 shares during the last quarter. AlphaCentric Advisors LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the third quarter worth $596,000. Commonwealth Equity Services LLC boosted its position in shares of Kiniksa Pharmaceuticals International by 2.2% during the third quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company’s stock worth $811,000 after acquiring an additional 237 shares during the last quarter. Finally, Chicago Partners Investment Group LLC purchased a new position in Kiniksa Pharmaceuticals International during the third quarter valued at $226,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Key Kiniksa Pharmaceuticals International News

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Negative Sentiment: Across October 30 and November 2, CAO Michael Megna, COO Ross Moat, CFO Mark Ragosa and insider John Paolini reported sales totaling about 272,600 shares, worth approximately $25.4 million. The selling could weigh on sentiment or temper the stock’s recent momentum. However, each transaction was made under a pre-arranged Rule 10b5-1 plan, so it is not necessarily a response to new company developments. Megna SEC filing Moat SEC filing Paolini SEC filing Ragosa SEC filing

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.